Unidisco, Inc. v. Schattner

824 F.2d 965, 3 U.S.P.Q. 2d (BNA) 1439
CourtCourt of Appeals for the Federal Circuit
DecidedJuly 29, 1987
DocketNos. 86-1682, 87-1001
StatusPublished
Cited by15 cases

This text of 824 F.2d 965 (Unidisco, Inc. v. Schattner) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Unidisco, Inc. v. Schattner, 824 F.2d 965, 3 U.S.P.Q. 2d (BNA) 1439 (Fed. Cir. 1987).

Opinion

BISSELL, Circuit Judge.

Unidisco, Inc., The Yeratex Corporation, and Chemed Corporation (collectively, Uni-disco) appeal, and Robert I. Schattner (Schattner) cross-appeals from the judg[966]*966ment of the United States District Court for the District of Maryland, 231 USPQ 593 (D.Md.1986) in favor of Schattner on the issues of patent infringement and tortious interference with contract, and in favor of Unidisco on the issue of unfair competition. We affirm-in-part and reverse-in-part.

BACKGROUND

Unidisco began this action seeking a declaratory judgment that Schattner’s patent No. 4,103,001 (the ’001 patent) was invalid. Schattner counterclaimed against Unidisco for patent infringement, tortious interference with contract, and unfair competition.

Sporicidin, the patented composition, is a liquid sterilant capable of killing all forms of microorganisms, including spores, within a given contact period. When diluted, Sporicidin can also be used as a disinfectant. When used as a disinfectant, it will kill non-spore microorganisms within a given contact period.

Representatives of Unidisco met with Schattner in late 1978 to discuss Unidisco’s marketing Sporicidin to the dental profession as a sterilant and dilutable disinfectant. At the same time, Schattner was also negotiating with another company, Girard, Inc. On December 26, 1978, Schattner granted Girard “an exclusive license to make, have made by others solely for Gir-ard’s use or sale hereunder, use and sell compositions covered by the [’001] Patent.” The license agreement also provided that “Girard's rights and obligations hereunder may not be assigned or sub-licensed without written approval of Schattner” until after certain payments described in the agreement had been made by Girard to Schattner.

On January 30, 1979, Girard entered into an exclusive distributorship agreement with Unidisco under which Unidisco purchased Sporicidin for resale to the dental market. Schattner learned in early 1979 that Unidisco was promoting itself as a distributor of Sporicidin. Nevertheless, he continued to accept royalties from Girard on sales made to Unidisco. He did not object to the agreement between Girard and Unidisco until June 4, 1979, when Schattner notified Girard of his intent to arbitrate the issue of an illegal sublicense, along with other disputes under the licensing agreement. In February 1980, the arbitrators declared the license agreement terminated and awarded Schattner $596,-000 which included royalties on Girard’s sales of Sporicidin to Unidisco that Schatt-ner later alleged were infringing.

During early 1980, Unidisco was in possession of approximately 14,000 quarts of Sporicidin. Unidisco’s sales efforts were hampered by an incorrect statement on the labels of the bottles of Sporicidin that it was approved by the American Dental Association (ADA) for use as a disinfectant when diluted with water in a ratio of thirty-to-one. Schattner had originally obtained ADA approval for use of Sporicidin as a disinfectant when diluted thirty-to-one, but upon further testing, it was discovered that when diluted thirty-to-one, the product was incapable of killing tubercule bacillus (TB). As a result, the ADA informed Schattner that the product was not approved as a disinfectant when diluted thirty-to-one. The labels on the bottles in Unidisco’s possession stated that the product could be used as a disinfectant when diluted thirty-to-one, but that, if TB were suspected, it should be used full strength. After February 20, 1980, both the ADA and the Environmental Protection Agency (EPA) approved Sporicidin as effective against TB when diluted sixteen-to-one. Schattner and Unidisco both wanted the correct dilution ratio stated on the labels. Unidisco prepared updated labels which were attached to the bottles with rubber bands and tape. Schattner did not approve of this method of re-labeling the bottles. Unidisco sold the re-labeled Sporicidin.

The case was tried before a jury for eleven weeks. The jury returned a verdict for Schattner on Unidisco’s claim of patent invalidity. Schattner counterclaimed that Unidisco willfully infringed the ’001 patent by selling the 14,000 quarts of Sporicidin under the distributorship agreement. The jury found the patent willfully infringed and awarded a reasonable royalty of $182,-000, which the court trebled. Schattner [967]*967counterclaimed that Unidisco had entered into a sublicensing agreement with Girard, and that by doing so, Unidisco had tortiously interfered with the contractual relationship between Schattner and Girard. On this counterclaim the jury awarded $1.00 nominal damages and $4,000,000 punitive damages. Finally, Schattner counterclaimed that Unidisco unfairly competed against him by affixing shoddy labels to the Sporicidin bottles and selling them to the public, while Unidisco was attempting to develop a product to compete with Spori-cidin. The jury found in Schattner’s favor on this counterclaim and awarded $1.00 as nominal damages and $6,000,000 punitive damages. The court applied District of Columbia law on all of the common law counterclaims.

The trial court entered judgment for Schattner on Unidisco’s claim of patent invalidity. Unidisco does not appeal that aspect of the judgment. Unidisco moved in the alternative for judgment notwithstanding the verdict (JNOV), new trial, or remit-titur with respect to Schattner’s counterclaims. The trial court denied the motions with respect to the patent infringement counterclaim. With respect to the tortious interference with contract counterclaim, the court granted the motion for JNOV in part, refusing to enter judgment for punitive damages, because District of Columbia law does not allow recovery of punitive damages in such cases based on an award of nominal damages. The court granted the motion for JNOV on the unfair competition counterclaim on the basis that Schatt-ner had failed to state a claim cognizable under the law of the District of Columbia. The trial court’s disposition of the motions for new trial and remittitur are not relevant to this appeal. In accordance with the court’s rulings on post trial motions, it entered judgment for Schattner on the patent infringement and tortious interference with contract counterclaims.

ISSUES

1.Does the sale of Sporicidin by Girard to Unidisco under an exclusive distributorship agreement, as a matter of law, constitute a sublicense?

2. Did the trial court err, as a matter of law, by denying Unidisco’s motion for JNOV on the issue of tortious interference with contract?

3. Did the trial court err, as a matter of law, by granting Unidisco’s motion for JNOV on the issue of unfair competition?

OPINION

I. Standard of Review

The issues in this appeal all turn on whether the trial court properly granted or denied motions for JNOV. This court reviews a judgment entered after the grant or denial of a motion for JNOV to determine whether the jury’s factual findings were supported by substantial evidence, or if so, whether the jury’s legal conclusions were supported by those facts. DMI, Inc. v. Deere & Co., 802 F.2d 421, 425, 231 USPQ 276, 278 (Fed.Cir.1986); Perkin Elmer Corp. v. Computervision Corp., 732 F.2d 888, 893, 221 USPQ 669, 673 (Fed. Cir.), cert. denied, 469 U.S.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
824 F.2d 965, 3 U.S.P.Q. 2d (BNA) 1439, Counsel Stack Legal Research, https://law.counselstack.com/opinion/unidisco-inc-v-schattner-cafc-1987.